StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report report published on Wednesday. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Up 0.7 %

Shares of TherapeuticsMD stock opened at $1.42 on Wednesday. The company has a fifty day moving average of $1.54 and a 200-day moving average of $1.74. TherapeuticsMD has a 52-week low of $1.15 and a 52-week high of $2.84.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.